Literature DB >> 19190624

Clinical and radiographic response to a local infliximab injection in a patient with chronic sacroiliitis.

Finbar D O'Shea1, Nigil Haroon, David C Salonen, Robert D Inman.   

Abstract

BACKGROUND: A 49-year-old man presented to a rheumatology clinic with a 2-month history of low back pain. The pain seemed to be inflammatory in origin, with nocturnal occurrence and substantial early morning stiffness. The patient was previously well, with no history of psoriasis, inflammatory bowel disease or iritis. INVESTIGATIONS: Physical examination, anteroposterior X-ray of the pelvis, isotope bone scan, CT and MRI of the sacroiliac joints, measurement of serum inflammatory markers, HLA-B27 testing, routine and mycobacterial culture of the sacroiliac joint fluid aspirate, tuberculosis skin testing and chest X-ray. DIAGNOSIS: An HLA-B27-negative patient with chronic unilateral sacroiliitis refractory to conventional management. MANAGEMENT: After unsuccessful treatment with various NSAIDs and physical therapy, local corticosteroid injections on two occasions in the affected sacroiliac joint provided transient relief. A subsequent 20 mg injection of infliximab into the affected joint resulted in clinical and radiological improvement that has been sustained for more than 2 years.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19190624     DOI: 10.1038/ncprheum1003

Source DB:  PubMed          Journal:  Nat Clin Pract Rheumatol        ISSN: 1745-8382


  12 in total

1.  Treatment of resistant rheumatoid arthritis by intra-articular infliximab injections: a pilot study.

Authors:  S N Nikas; T I Temekonidis; A K Zikou; M I Argyropoulou; S Efremidis; A A Drosos
Journal:  Ann Rheum Dis       Date:  2004-01       Impact factor: 19.103

2.  Local infusion of infliximab for the treatment of acute joint inflammation.

Authors:  M Bokarewa; A Tarkowski
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

3.  Intraarticular injection of infliximab.

Authors:  Grigorios T Sakellariou; Giasna Kakavouli; Ioannis Chatzigiannis
Journal:  J Rheumatol       Date:  2006-09       Impact factor: 4.666

4.  Should we be using intraarticular tumor necrosis factor blockade in inflammatory monoarthritis?

Authors:  Benjamin A C Fisher; Andrew Keat
Journal:  J Rheumatol       Date:  2006-10       Impact factor: 4.666

5.  Effect of intra-articular infliximab on synovial membrane pathology in a patient with a seronegative spondyloarthropathy.

Authors:  M J Ahern; D G Campbell; H Weedon; V Papangelis; M D Smith
Journal:  Ann Rheum Dis       Date:  2008-04-13       Impact factor: 19.103

6.  Successful treatment with multiple intra-articular injections of infliximab in a patient with psoriatic arthritis.

Authors:  P Alstergren; P T Larsson; S Kopp
Journal:  Scand J Rheumatol       Date:  2008 Mar-Apr       Impact factor: 3.641

7.  Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab.

Authors:  Lieve Schatteman; Lieve Gyselbrecht; Luc De Clercq; Herman Mielants
Journal:  J Rheumatol       Date:  2005-11-15       Impact factor: 4.666

8.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Authors:  S van der Linden; H A Valkenburg; A Cats
Journal:  Arthritis Rheum       Date:  1984-04

9.  The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy.

Authors:  M Dougados; S van der Linden; R Juhlin; B Huitfeldt; B Amor; A Calin; A Cats; B Dijkmans; I Olivieri; G Pasero
Journal:  Arthritis Rheum       Date:  1991-10

10.  Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.

Authors:  J Braun; X Baraliakos; J Listing; C Fritz; R Alten; G Burmester; A Krause; S Schewe; M Schneider; H Sörensen; H Zeidler; J Sieper
Journal:  Ann Rheum Dis       Date:  2007-10-29       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.